As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.


French German Italian Portuguese Russian

Non-Hodgkin Lymphoma

Assessing the Anti-Tumor Activity and Safety of REGN1979 in Patients with Relapsed or Refractory Follicular Lymphoma

Assessing the anti-tumor activity and safety of REGN1979 in patients with relapsed or refractory follicular lymphoma.

Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype Treatment Study

A randomized double-blind phase III study of ibrutinib during and following autologous stem cell transplantation versus placebo in patients with relapsed or refractory diffuse large B-cell lymphoma of the activated B-cell subtype.

Diffuse Large B-Cell Lymphoma Treatment Study

A phase 2 study of the combination of ublituximab + TGR-1202 and TG-1202 alone in patients with previously treated diffuse large B-cell lymphoma.

Drug Treatment Study for High Grade B-Cell Lymphomas

Randomized phase II/III study of venetoclax (ABT199) plus chemoimmunotherapy for MYC/BCL2 double-hit and double expressing lymphomas.

Drug Treatment Study for Patients with Follicular Lymphoma

Study of ME-401 in subjects with follicular lymphoma after failure of two or more prior therapies.

Follicular Lymphoma Treatment Study

Study of ibrutinib and rituximab in subjects whose follicular lymphoma has not been treated before.

Mantle Cell Lymphoma Treatment Study

Rituximab with or without stem cell transplant in mantle cell lymphoma.

MYC-Associated B-Cell Lymphomas Treatment Study

Prospective, multi-center phase I/II trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated B-cell lymphomas.

Nivolumab and Combination Chemotherapy in Treating Participants with Diffuse Large B-Cell Lymphoma

Nivolumab and combination chemotherapy in treating participants with diffuse large B-cell lymphoma.

Relapsed or Refractory Follicular Lymphoma Treatment Study

Obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy in treating patients with relapsed or refractory follicular lymphoma.